2023年5月16日

Anavo療法——一個全球領先的打開人類磷酸酶生物學治療的潛力——最近宣布一個€850萬種子圓形擴展,增加推廣投資基金作為一種新的投資者。和所有現有投資者,M公司、INKEF Taiho Ventures和Bioqube企業,參與了擴展,使總種子€2800萬。與資金,卡琳Kleinhans,推廣企業基金的合夥人將加入現有的董事會,其中包括查爾斯·麥克德莫特(主席);Therese瑪麗亞列支敦士登,M公司;西蒙實現INKEF資本;淺沼的榮,Taiho企業;黛博拉杜蒙特Bioqube企業;和Birgit澤赫,Anavo療法。Anavo療法被稱為第一家係統藥物磷酸酶,這是一個豐富的目標空間無藥可治之前考慮了幾十年。該公司吸引了世界領先的科學技術phosphatase-driven疾病生物學和藥物發現解鎖phosphatase-targeted全部潛能的變構調節器。 In oncology, Anavo has been developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. KEY QUOTES: “Since our inception in 2021, Anavo Therapeutics has advanced multiple proprietary pipeline programs in this centrally important target class and added significant expertise to the team, SAB, and the board. Today, we welcome MRL Ventures Fund to our existing investor syndicate. Leveraging our unique IGNITE phosphatase drug discovery platform, we will continue to accelerate our proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development, while continuing to build a center of excellence for phosphatase targeting.” — Birgit Zech, PhD, Chief Executive Officer of Anavo Therapeutics “We are encouraged by the progress being made at Anavo in establishing a systematic approach to phosphatase drug discovery. At MRL Ventures we believe Anavo’s platform offers the potential to harness the therapeutic opportunity of this important target class.” — Karin Kleinhans, PhD, Partner at MRL Ventures Fund Trending on Pulse 2.0